Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00920985 · ClinicalTrials.gov registry record · Phase 3
US Cycle Control and Blood Pressure Study
A Phase 3 study, sponsored by Bayer.
- Completed
- Registry status
- Phase 3
- Development phase
- 346
- Enrollment target
NCT00920985: Completed Phase 3 study, sponsored by Bayer.
NCT00920985 is a Phase 3 study that has completed, run by Bayer. The registered enrollment target is 346 participants, below the 772-participant average among 15,282 other Phase 3 trials with a reported enrollment target (55% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00920985, a Phase 3 study, has completed, sponsored by Bayer.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 346 participants
- Enrollment target
Study Summary
Birth Control Patch Study
Interventions
- DRUG Gestodene/EE (FC Patch Low, BAY86-5016)
- DRUG Oral contraceptive (equivalent to the active treatment tablets of Levlite), 21-day blister SH D00593A
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 346 participants |
| Start Date | 2009-06 |
| Est. Completion | 2010-09 |
| Phase | Phase 3 |
What the finished NCT00920985 record still lists
NCT00920985 is an interventional study that assigns participants to a tested intervention. The registered 346 participants enrollment target is mid-sized for trials with a published cap, below the 772-participant average among 15,282 other Phase 3 trials with a reported enrollment target (55% lower).
The record links to 0 conditions, and to 2 interventions - of which Gestodene/EE (FC Patch Low, BAY86-5016) is the first listed.
NCT00920985 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT00920985 about?
NCT00920985 is a clinical study titled "US Cycle Control and Blood Pressure Study". Birth Control Patch Study
What is the current status of trial NCT00920985?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 346 participants. The study started on 2009-06. Estimated completion is 2010-09.
What interventions are being tested in trial NCT00920985?
The interventions under investigation include: Gestodene/EE (FC Patch Low, BAY86-5016) (DRUG), Oral contraceptive (equivalent to the active treatment tablets of Levlite), 21-day blister SH D00593A (DRUG).
Who is sponsoring clinical trial NCT00920985?
This trial is sponsored by Bayer, which has 591 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT00920985's enrollment target sits among peer trials
346 1049th of 2000 higher than 951 of 2,000 other Phase 3 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 3 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT05267886 · 346 participants · Phase 4
CAPITAL DOREMI 2: Inotrope Versus Placebo Therapy for Cardiogenic Shock
- NCT06705842 · 346 participants · Phase 4
APPI-Cost Trial for Perforated Appendicitis
- NCT06932887 · 346 participants · Phase 3
The Beat Pain Better Trial
- NCT01742143 · 347 participants
Impact of ICCAN on Cancer Treatment Completion and Quality of Life
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia